Betukladin (BAA)

2021: Start of deliveries to Russian hospitals

At the end of November 2021, it became known about the start of deliveries to Russian hospitals of the Betukladin biopreparation, created from berries and bark for the treatment of COVID-19. This is the development of Yakut scientists of the Institute of Biological Problems of Cryolithozone of the Siberian Branch of the Russian Academy of Sciences.

As Tatyana Salova, Deputy General Director for Science and Development Programs of the Yakutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, told Prime Agency, large-scale production of the drug is being prepared, after which it will appear on sale in Yakutsk and, most likely, in other regions of the Russian Federation.

The drug COVID-19 from birch and Betukladin jagel began to be supplied to hospitals in Russia

Preparation represents biologically active additive, which includes betulin, obtained from birch bark, lichen oligosaccharides, which remove toxins from body, have anticoagulation and immunomodulatory action, increase digestibility of betulin and other active substances of complex. In addition, secondary lichen substances are present in the additive, which have a mild antibacterial effect.

Initially, Yakut scientists began developing a biologic preparation for the prevention in the treatment of hepatitis and multidrug-resistant pulmonary tuberculosis and the most dangerous of serum hepatitis - hepatitis "B + D." However, during clinical trials, Betucladin has also proven itself as an effective means of preventing and recovering from coronavirus (COVID-19) infection.

According to experts, the drug reduces and facilitates the course of the disease, stops the development of "fatigue syndrome" and depression at the stage of rehabilitation after coronavirus disease.

State registration in Russia of the drug "Betukladin" was held in November 2021. By this time, he had passed the second stage of clinical trials.^[1]

Notes